Journal: mBio

Article Title: Functional Analysis of the Human Antibody Response to Meningococcal Factor H Binding Protein

doi: 10.1128/mBio.00842-15

Figure Lengend Snippet: Serum antibodies from an adult human boosted with a serogroup B vaccine containing FHbp enhance FH binding. A healthy adult was immunized with a third dose of a serogroup B vaccine (4CMenB; Novartis Vaccines) which contained FHbp ID 1 in variant group 1. The vaccine was given 6 years after doses 1 and 2. (A) IgG binding to FHbp (ELISA) in serum samples obtained 2 weeks before (open circles) and 3 weeks after (open diamonds) dose 3. Negative-control serum (filled squares) was from a nonvaccinated adult. (B) Binding of serum FH to serogroup B strain H44/76. All sera were heated to inactivate endogenous complement (FH is stable under the conditions used ). Gray histogram, bacteria without serum; solid line, 1:600 dilution of serum obtained 2 weeks before dose 3; dashed line, 1:600 dilution of serum obtained 3 weeks after dose 3. (C) Binding of human FH to strain H44/76 incubated with a 1:600 dilution of post-dose 3 serum that had been depleted of anti-FHbp antibodies (solid line) or with a 1:600 dilution of the adsorbed serum mixed with 0.1 µg/ml of affinity-purified anti-FHbp antibodies eluted from the FHbp-Sepharose used for antibody depletion (dotted line). The gray histogram represents background binding to bacteria in the absence of FH or serum (secondary antibody alone).

Article Snippet: This strain is mismatched for all of the other antigens in the Novartis 4CMenB vaccine ( , ).

Techniques: Binding Assay, Variant Assay, Enzyme-linked Immunosorbent Assay, Negative Control, Incubation, Affinity Purification

Journal: Acta Biomaterialia

Article Title: Engineering DNA vaccines against infectious diseases

doi: 10.1016/j.actbio.2018.08.033

Figure Lengend Snippet: Recent licensed protein and DNA vaccine therapies (data extracted from 2001 to 2017; some of which are not related to infectious diseases).

Article Snippet: Recombinant proteins , Meningococcal Group B , Bexsero® , Intramuscular , 2015 , Novartis.

Techniques: Virus, Recombinant

Journal: Medicines

Article Title: Sexually Transmitted Neisseria gonorrhoeae Infections—Update on Drug Treatment and Vaccine Development

doi: 10.3390/medicines8020011

Figure Lengend Snippet: Potential Antigen Targets for Gonorrhea Vaccine and Drug Development.

Article Snippet: A recent investigation expanded on the New Zealand findings by demonstrating that individuals immunized with the new four-component meningococcal group B vaccine 4CMenB, trade name Bexsero ® (GlaxoSmithKline), induced antibodies in humans that specifically recognized gonococcal proteins [ ].

Techniques: Functional Assay, Binding Assay, In Vitro, Membrane, Adjuvant, Generated, Glycoproteomics, Library Screening, Infection, Ex Vivo, In Silico, Activity Assay, Translocation Assay, Blocking Assay, Vaccines, Control, Recombinant